Screener
Enovis ENOV Prevention & Recovery — Adjusted EBITDA (non-GAAP)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Enovis in its filing.
Tagged under the XBRL concept cfx:SegmentOperatingIncome.
The source filing: Enovis’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001420800-26-000035
| Line item | Three Months Ended / July 3, 2026 | Three Months Ended / July 4, 2025 | Six Months Ended / July 3, 2026 | Six Months Ended / July 4, 2025 |
|---|---|---|---|---|
| Segment operating expense | 111,250 | 107,523 | 223,720 | 215,367 |
| Total segment expenses | 243,050 | 248,528 | 489,024 | 494,377 |
| Add: Depreciation | 5,129 | 4,689 | 10,194 | 8,857 |
| Adjusted EBITDA (non-GAAP) | $50,327 | $46,731 | $81,436 | $77,634 |
| Reconstructive: | ||||
| Net sales | $294,534 | $273,975 | $611,667 | $560,225 |
| Segment cost of sales | 98,873 | 97,750 | 196,208 | 195,024 |
| Segment research and development | 23,980 | 21,031 | 47,766 | 40,318 |
Item 1. Financial Statements
FAQ
- What is Enovis's prevention & recovery — adjusted EBITDA (non-gaap)?
- Enovis (ENOV) reported prevention & recovery — adjusted EBITDA (non-gaap) of $50.33M in Q2 2026.
- What does prevention & recovery — adjusted EBITDA (non-gaap) mean?
- This non-GAAP measure represents the operating profitability of the Prevention & Recovery segment before interest, taxes, depreciation, and amortization, adjusted for non-recurring or non-cash items. It serves as a primary indicator of the segment's core operational performance and cash-generating capability, excluding the impact of financing decisions and accounting conventions. Investors use this to evaluate the underlying health and scalability of the rehabilitation and recovery business.
Ask your AI about Enovis's prevention & recovery — adjusted ebitda (non-gaap).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude